Black Diamond Therapeutics is a medical company focused on analyzing genetically defined cancers.
Black Diamond Therapeutics has raised $75.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2023.
Black Diamond Therapeutics's investors include RA Capital Management, Wellington Management, Janus Henderson Investors, New Enterprise Associates, Perceptive Advisors.
Black Diamond Therapeutics is headquartered in Cambridge, United States.
Black Diamond Therapeutics is a medical company focused on analyzing genetically defined cancers.
Black Diamond Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Black Diamond Therapeutics — Funding & Investors." VCBacked, June 29, 2023, https://www.vcbacked.co/company/black-diamond-therapeutics. Accessed August 14, 2026.
VCBacked. (2023). Black Diamond Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/black-diamond-therapeutics
{{cite web |title=Black Diamond Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/black-diamond-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated